Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 4 (2007), Issue 8 (August)

1. Additional double reading of screening mammograms by radiologic technologists: impact on screening performance parameters.
   J Natl Cancer Inst, 99(15): 1162-70. [Abstract] [Full-text]
2. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.
   J Natl Cancer Inst, 99(15): 1152-61. [Abstract] [Full-text]
3. Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women.
   J Natl Cancer Inst, 99(15): 1178-87. [Abstract] [Full-text]
4. Mediastinal carcinosis involving the esophagus in breast cancer: the "breast-esophagus" syndrome: report on 25 cases and guidelines for diagnosis and treatment.
   Ann Surg, 246(2): 316-22. [Abstract] [Full-text]
5. The impact of a change in Medicare reimbursement policy and HEDIS measures on stage at diagnosis among Medicare HMO and fee-for-service female breast cancer patients.
   Med Care, 45(8): 761-6. [Abstract] [Full-text]
6. Trastuzumab use for metastatic breast cancer in pregnancy.
   Obstet Gynecol, 110(2): 507-10. [Abstract] [Full-text]
7. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.
   Cancer Res, 67(15): 7477-86. [Abstract] [Full-text]
8. Isoobtusilactone A induces cell cycle arrest and apoptosis through reactive oxygen species/apoptosis signal-regulating kinase 1 signaling pathway in human breast cancer cells.
   Cancer Res, 67(15): 7406-20. [Abstract] [Full-text]
9. Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways.
   Cancer Res, 67(15): 7386-94. [Abstract] [Full-text]
10. Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1.
    Cancer Res, 67(15): 7256-65. [Abstract] [Full-text]
11. Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2.
    Cancer Res, 67(15): 7238-46. [Abstract] [Full-text]
12. Silencing of FLRG, an antagonist of activin, inhibits human breast tumor cell growth.
    Cancer Res, 67(15): 7223-9. [Abstract] [Full-text]
13. Krüppel-like factor 8 induces epithelial to mesenchymal transition and epithelial cell invasion.
    Cancer Res, 67(15): 7184-93. [Abstract] [Full-text]
14. Prevention of surgical site infection after breast cancer surgery by targeted prophylaxis antibiotic in patients at high risk of surgical site infection.
    J Surg Oncol, 96(2): 124-9. [Abstract] [Full-text]
15. Should adjuvant radiotherapy to the supraclavicular fossa be routinely given in patients with breast conservative treatment?
    J Surg Oncol, 96(2): 144-50. [Abstract] [Full-text]
16. "Wide local ablation" of localized breast cancer using high intensity focused ultrasound.
    J Surg Oncol, 96(2): 130-6. [Abstract] [Full-text]
17. The incidence, indications and outcome for the non-operative management of breast cancer.
    J Surg Oncol, 96(2): 137-43. [Abstract] [Full-text]
18. Quantitative and clinical description of postural instability in women with breast cancer treated with taxane chemotherapy.
    Arch Phys Med Rehabil, 88(8): 1002-8. [Abstract] [Full-text]
19. Genomic instability and increased expression of BUB1B and MAD2L1 genes in ductal breast carcinoma.
    Cancer Lett, 254(2): 298-307. [Abstract] [Full-text]
20. Enhanced anticancer effect of conjugated linoleic acid by conjugation with Pluronic F127 on MCF-7 breast cancer cells.
    Cancer Lett, 254(2): 244-54. [Abstract] [Full-text]
21. Human bone marrow stromal cells enhance breast cancer cell growth rates in a cell line-dependent manner when evaluated in 3D tumor environments.
    Cancer Lett, 254(2): 255-64. [Abstract] [Full-text]
22. Docetaxel-ifosfamide combination in patients with HER2-non-overexpressing advanced breast cancer failing prior anthracyclines.
    Invest New Drugs, 25(5): 463-70. [Abstract] [Full-text]
23. Control of the growth of human breast cancer cells in culture by manipulation of arachidonate metabolism.
    BMC Cancer, 7: 138. [Abstract] [Full-text]
24. Origin and distribution of the BRCA2-8765delAG mutation in breast cancer.
    BMC Cancer, 7: 132. [Abstract] [Full-text]
25. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database.
    Cancer, 110(4): 876-84. [Abstract] [Full-text]
26. Cost effectiveness of mammography screening for Chinese women.
    Cancer, 110(4): 885-95. [Abstract] [Full-text]
27. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection.
    Cancer, 110(4): 723-30. [Abstract] [Full-text]
28. Metastases to the breast from nonbreast solid neoplasms: presentation and determinants of survival.
    Cancer, 110(4): 731-7. [Abstract] [Full-text]
29. Effects of supervised exercise training on cardiopulmonary function and fatigue in breast cancer survivors during and after treatment.
    Cancer, 110(4): 918-25. [Abstract] [Full-text]
30. Breast cancer among immigrants: a systematic review and new research directions.
    J Immigr Minor Health, 9(4): 307-22. [Abstract] [Full-text]
31. Punjabi immigrant women's breast cancer stories.
    J Immigr Minor Health, 9(4): 269-79. [Abstract] [Full-text]
32. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
    J Clin Oncol, 25(23): 3525-33. [Abstract] [Full-text]
33. Receipt of appropriate primary breast cancer therapy and adjuvant therapy are not associated with obesity in older women with access to health care.
    J Clin Oncol, 25(23): 3428-36. [Abstract] [Full-text]
34. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
    J Clin Oncol, 25(23): 3399-406. [Abstract] [Full-text]
35. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.
    J Clin Oncol, 25(23): 3407-14. [Abstract] [Full-text]
36. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.
    J Clin Oncol, 25(23): 3415-20. [Abstract] [Full-text]
37. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes.
    J Clin Oncol, 25(23): 3421-7. [Abstract] [Full-text]
38. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer.
    J Clin Oncol, 25(23): 3440-7. [Abstract] [Full-text]
39. Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004.
    J Clin Oncol, 25(23): 3437-9. [Abstract] [Full-text]
40. Referral patterns, cancer diagnoses, and waiting times after introduction of two week wait rule for breast cancer: prospective cohort study.
    BMJ, 335(7614): 288. [Abstract] [Full-text]
41. MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study.
    Lancet, 370(9586): 485-92. [Abstract] [Full-text]
42. Validation of clinical prediction rules for a low probability of nonsentinel and extensive lymph node involvement in breast cancer patients.
    Am J Surg, 194(3): 288-93. [Abstract] [Full-text]
43. Cobaltous chloride and hypoxia inhibit aryl hydrocarbon receptor-mediated responses in breast cancer cells.
    Toxicol Appl Pharmacol, 223(1): 28-38. [Abstract] [Full-text]
44. RNA interference-mediated knockdown of DNMT1 and DNMT3B induces CXCL12 expression in MCF-7 breast cancer and AsPC1 pancreatic carcinoma cell lines.
    Cancer Lett, 255(1): 153-9. [Abstract] [Full-text]
45. Progesterone, glucocorticoid, but not estrogen receptor mRNA is altered in breast cancer stroma.
    Cancer Lett, 255(1): 77-84. [Abstract] [Full-text]
46. Identification of arsenic-binding proteins in human breast cancer cells.
    Cancer Lett, 255(1): 95-106. [Abstract] [Full-text]
47. Letrozole: present and future role in the treatment of breast cancer.
    Expert Opin Pharmacother, 8(12): 1965-75. [Abstract] [Full-text]
48. Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials.
    Clin Cancer Res, 13(16): 4943-8. [Abstract] [Full-text]
49. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.
    Clin Cancer Res, 13(16): 4909-19. [Abstract] [Full-text]
50. One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients.
    Clin Cancer Res, 13(16): 4807-16. [Abstract] [Full-text]
51. Epigenetic modulation of estrogen receptor-alpha by pRb family proteins: a novel mechanism in breast cancer.
    Cancer Res, 67(16): 7731-7. [Abstract] [Full-text]
52. Photochemical internalisation of chemotherapy potentiates killing of multidrug-resistant breast and bladder cancer cells.
    Br J Cancer, 97(4): 502-12. [Abstract] [Full-text]
53. Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis.
    Br J Cancer, 97(4): 479-85. [Abstract] [Full-text]
54. How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults.
    J Clin Oncol, 25(24): 3705-11. [Abstract] [Full-text]
55. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.
    J Clin Oncol, 25(24): 3699-704. [Abstract] [Full-text]
56. Trastuzumab and metastatic breast cancer: trastuzumab use in Australia--monitoring the effect of an expensive medicine access program.
    J Clin Oncol, 25(24): 3688-93. [Abstract] [Full-text]
57. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.
    J Clin Oncol, 25(24): 3680-7. [Abstract] [Full-text]
58. Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation.
    J Clin Oncol, 25(24): 3670-9. [Abstract] [Full-text]
59. Patient satisfaction with treatment of breast cancer: does surgeon specialization matter?
    J Clin Oncol, 25(24): 3694-8. [Abstract] [Full-text]
60. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011.
    J Clin Oncol, 25(24): 3657-63. [Abstract] [Full-text]
61. Immunohistochemical expression of RARalpha, RARbeta, and Cx43 in breast tumor cell lines after treatment with lycopene and correlation with RT-QPCR.
    J Histochem Cytochem, 55(9): 877-83. [Abstract] [Full-text]
62. Increased skin dose with the use of a custom mattress for prone breast radiotherapy.
    Med Dosim, 32(3): 196-9. [Abstract] [Full-text]
63. Phosphorylation-dependent sumoylation of estrogen-related receptor alpha1.
    Biochemistry, 46(34): 9795-804. [Abstract] [Full-text]
64. Digital breast tomosynthesis: initial experience in 98 women with abnormal digital screening mammography.
    AJR Am J Roentgenol, 189(3): 616-23. [Abstract] [Full-text]
65. Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer.
    Expert Opin Pharmacother, 8(13): 2189-204. [Abstract] [Full-text]
66. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
    Oncogene, 26(39): 5793-807. [Abstract] [Full-text]
67. p38MAPK-activated AKT in HER-2 overexpressing human breast cancer cells acts as an EGF-independent survival signal.
    J Surg Res, 142(1): 162-9. [Abstract] [Full-text]
68. Squamous cell carcinoma in situ of the breast: a light microscopic and immunohistochemical study of a previously undescribed lesion.
    Am J Surg Pathol, 31(9): 1414-9. [Abstract] [Full-text]
69. A gold(I) phosphine complex selectively induces apoptosis in breast cancer cells: implications for anticancer therapeutics targeted to mitochondria.
    Biochem Pharmacol, 74(7): 992-1002. [Abstract] [Full-text]
70. Autophagic cell death, polyploidy and senescence induced in breast tumor cells by the substituted pyrrole JG-03-14, a novel microtubule poison.
    Biochem Pharmacol, 74(7): 981-91. [Abstract] [Full-text]
71. Moesin expression is a marker of basal breast carcinomas.
    Int J Cancer, 121(8): 1779-85. [Abstract] [Full-text]
72. Tissue microarray analysis of connexin expression and its prognostic significance in human breast cancer.
    Cancer Lett, 255(2): 284-94. [Abstract] [Full-text]
73. Distress reduction from a psychological intervention contributes to improved health for cancer patients.
    Brain Behav Immun, 21(7): 953-61. [Abstract] [Full-text]
74. Pattern of serum immunoreactivity against breast cancer cell lysates may predict severity of disease in breast cancer patients.
    Cancer Immunol Immunother, 56(11): 1711-21. [Abstract] [Full-text]
75. NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy.
    Cancer Immunol Immunother, 56(11): 1723-31. [Abstract] [Full-text]
76. Mechanisms of disease: angiogenesis and the management of breast cancer.
    Nat Clin Pract Oncol, 4(9): 536-50. [Abstract] [Full-text]
77. Origins of breast cancer subtypes and therapeutic implications.
    Nat Clin Pract Oncol, 4(9): 516-25. [Abstract] [Full-text]
78. Analysis of blood flow and glucose metabolism in mammary carcinomas and normal breast: a H2(15)O PET and 18F-FDG PET study.
    Nucl Med Commun, 28(10): 789-97. [Abstract] [Full-text]
79. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer.
    J Clin Oncol, 25(25): 3877-83. [Abstract] [Full-text]
80. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy.
    J Clin Oncol, 25(25): 3866-70. [Abstract] [Full-text]
81. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer.
    J Clin Oncol, 25(25): 3837-45. [Abstract] [Full-text]
82. What is the psychological impact of mammographic screening on younger women with a family history of breast cancer? Findings from a prospective cohort study by the PIMMS Management Group.
    J Clin Oncol, 25(25): 3823-30. [Abstract] [Full-text]
83. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.
    J Clin Oncol, 25(25): 3816-22. [Abstract] [Full-text]
84. Shifting breast cancer trends in the United States.
    J Clin Oncol, 25(25): 3923-9. [Abstract] [Full-text]
85. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
    J Clin Oncol, 25(25): 3846-52. [Abstract] [Full-text]
86. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.
    J Clin Oncol, 25(25): 3853-8. [Abstract] [Full-text]
87. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
    J Clin Oncol, 25(25): 3808-15. [Abstract] [Full-text]
88. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk.
    J Clin Oncol, 25(25): 3871-6. [Abstract] [Full-text]
89. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
    J Clin Oncol, 25(25): 3859-65. [Abstract] [Full-text]
90. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.
    J Clin Oncol, 25(25): 3831-6. [Abstract] [Full-text]
91. Nonsteroidal antiinflammatory drug use and breast cancer risk: subgroup findings.
    Am J Epidemiol, 166(6): 709-16. [Abstract] [Full-text]
92. Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma.
    Cancer Sci, 98(10): 1570-6. [Abstract] [Full-text]
93. Pilot study of MDR1 gene transfer into hematopoietic stem cells and chemoprotection in metastatic breast cancer patients.
    Cancer Sci, 98(10): 1609-16. [Abstract] [Full-text]
94. Expression level of insulin-like growth factor binding protein 5 mRNA is a prognostic factor for breast cancer.
    Cancer Sci, 98(10): 1592-6. [Abstract] [Full-text]
95. Epigenetic silencing of claudin-6 promotes anchorage-independent growth of breast carcinoma cells.
    Cancer Sci, 98(10): 1557-62. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.